COVANCE INC. |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 2014 | Covance : Dow, S&P 500 close slightly lower; semis boost Nasdaq | RE |
| 2014 | Covance : LabCorp to pay $6.1 billion for drug trial company Covance | RE |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Corporate Officer/Principal | - | 06/23/06 | |
Hong Gang Bi
PRN | Corporate Officer/Principal | - | 01/07/01 |
| Corporate Officer/Principal | 63 | 18/12/18 | |
Thomas G. Turi
PRN | Corporate Officer/Principal | - | 01/08/01 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Glenn Eisenberg
BRD | Director/Board Member | 62 | 19/15/19 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 82,842,141 | 56,052,052 ( 67.66 %) | 25,882,990 ( 31.24 %) | 67.66 % |
Company contact information
Labcorp Drug Development, Inc.
206 Carnegie Center
08540-6233, Princeton
+336-584-5171
http://www.covance.com
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| +38.65% | 3.91TCr | |
| -9.17% | 3.88TCr | |
| +27.24% | 3.12TCr | |
| +11.16% | 2.59TCr | |
| -13.50% | 2.58TCr | |
| +43.79% | 1.41TCr | |
| +34.80% | 1.31TCr | |
| -7.99% | 1.13TCr | |
| -13.06% | 1.07TCr |
- Stock Market
- Equities
- Stock
- Company Covance Inc.
